What is Ablexis?
Ablexis operates at the intersection of genetic engineering and pharmaceutical research, providing a next-generation transgenic mouse platform known as the AlivaMab-X Mouse. This technology is engineered to elicit expanded immune responses, which are essential for the efficient identification of high-quality therapeutic antibodies. By offering tailored licensing options, Ablexis serves a diverse portfolio of clients, ranging from emerging biotechnology startups to established pharmaceutical giants. The company's core value proposition lies in its ability to streamline the early stages of drug development, effectively reducing the time and complexity associated with bringing novel biologics to clinical trials. Its market position is defined by its commitment to scientific rigor and its role as a foundational partner in the antibody discovery pipeline.
How much funding has Ablexis raised?
Ablexis has raised a total of $12M across 1 funding round:
Series A
$12M
Series A (2010): $12M with participation from Third Rock Ventures
Key Investors in Ablexis
Third Rock Ventures
Third Rock Ventures is a prominent healthcare venture firm that specializes in launching and building companies focused on disruptive science and medicine. They combine scientific vision with operational expertise to transform bold ideas into successful, patient-centric business enterprises.
What's next for Ablexis?
Looking ahead, the recent capital injection is expected to drive further innovation in the AlivaMab-X platform, potentially expanding the scope of its immune response capabilities. Ablexis is likely to focus on deepening its strategic partnerships, providing more robust support for its licensees as they navigate the complexities of antibody-derivative drug development. As the company continues to refine its technology, it remains a pivotal player in the biopharmaceutical ecosystem, poised to influence the next wave of therapeutic breakthroughs. The focus will remain on operational excellence and the continued validation of its platform through successful client outcomes, ensuring long-term sustainability and growth in the competitive landscape of drug discovery.
See full Ablexis company page
